InrebicActive Ingredient(s): Fedratinib Hydrochloride
FDA Approved: * August 16, 2019
Pharm Company: * IMPACT BIOMEDICINES INC
Fedratinib, sold under the brand name Inrebic, is an anti-cancer medication used to treat myeloproliferative diseases including myelofibrosis. It is used in the form of fedratinib hydrochloride capsules that are taken by mouth. It is a semi-selective inhibitor of Janus kinase 2 (JAK-2). It was approved by the FDA on 16 August 2019. Myelofibrosis is a myeloid cancer associated with anemia, splenomegaly, and constitutio... [wikipedia]* May have multiple approval dates, manufacturers, or labelers.